Claimed effect · Mazdutide

Does Mazdutide help with body weight?

A
Grade A — established in humans2 phase 3 RCTs · effect size: large
Short answerEstablished in humans. 2 phase 3 RCTs point the same way: a large effect. GLORY-1, 610 Chinese adults, 48 weeks: −12.0% (4 mg) and −14.8% (6 mg) versus −0.5% placebo; at least 5% loss in 73.5%, 82.8% and 11.5%. GLORY-2, 461 adults, 60 weeks on 9 mg: −16.65% versus −1.50%; 84.3% versus 33.1% lost at least 5%.

What the studies show

GLORY-1, 610 Chinese adults, 48 weeks: −12.0% (4 mg) and −14.8% (6 mg) versus −0.5% placebo; at least 5% loss in 73.5%, 82.8% and 11.5%. GLORY-2, 461 adults, 60 weeks on 9 mg: −16.65% versus −1.50%; 84.3% versus 33.1% lost at least 5%.

“At week 48, the mean percentage change in body weight from baseline was -11.00% (95% CI, -12.27 to -9.73) in the 4-mg mazdutide group, -14.01% (95% CI, -15.36 to -12.66) in the 6-mg mazdutide group, and 0.30% (95% CI, -0.98 to 1.58) in the placebo group, and 35.7%, 49.5%, and 2.0% of the participants, respectively, had a weight reduction of at least 15% (P<0.001 for all comparisons with placebo).”

Verbatim, from the abstractJi L, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1). N Engl J Med, 2025; DOI 10.1056/NEJMoa2411528

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1
    Ji L, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1).N Engl J Med, 2025; DOI 10.1056/NEJMoa2411528610 adults, 48 weeks.
  2. 2

In context

Mazdutide is a once-weekly GLP-1/glucagon dual agonist developed by Innovent with Lilly. In the 610-person GLORY-1 trial, published in the New England Journal of Medicine in May 2025, it produced 14.8% weight loss at 48 weeks on 6 mg against 0.5% on placebo; a 9 mg dose reached 16.7% at 60 weeks in the peer-reviewed GLORY-2 trial. China's regulator approved it for chronic weight management on 27 June 2025 and later for type 2 diabetes. It is not approved in the US, EU or UK.

Mazdutide is approved in china only. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Mazdutide proven to help with body weight?
Yes, as far as human trials can show it: 2 phase 3 RCTs. LYO grades this outcome A.
What studies are behind the grade?
GLORY-1, 610 Chinese adults, 48 weeks: −12.0% (4 mg) and −14.8% (6 mg) versus −0.5% placebo; at least 5% loss in 73.5%, 82.8% and 11.5%. GLORY-2, 461 adults, 60 weeks on 9 mg: −16.65% versus −1.50%; 84.3% versus 33.1% lost at least 5%.
Is Mazdutide approved for this?
Mazdutide is an approved medicine (Approved in China only); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Mazdutide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →